Fox Chase Cancer Center
2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertinib Highly Effective and Practice Changing in Stage IB/II/IIIA EGFRm NSCLC After Complete Tumor Resection?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Hossein Borghaei
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Hossein Borghaei
Login to view comments.
Click here to Login